Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference

Human Gene Therapy

Volumn 24, Issue 8, 2013, Pages 739-750

  Sun, Cheng Pu ^a,b,c   Wu, Tzu Hui ^c,d   Chen, Chun Chi ^c,f   Wu, Ping Yi ^c   Shih, Yao Ming ^c,d   Tsuneyama, Koichi ^e   Tao, Mi Hua ^a,b,c  

^a Taiwan International Graduate Program   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e UNIVERSITY OF TOYAMA   (Japan)

^f INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS U6; ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALBUMIN; CHEMOKINE; CYTOKINE; MICRORNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FLOW; FLOW CYTOMETRY; GENE OVEREXPRESSION; GRANULOCYTE; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE; LIVER TOXICITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RNA INTERFERENCE; RNA SEQUENCE; SOUTHERN BLOTTING; VIRAL GENE DELIVERY SYSTEM; VIRUS PATHOGENESIS; WILD TYPE;

ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; DRUG-INDUCED LIVER INJURY; FLOW CYTOMETRY; GENETIC VECTORS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84882327125     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.239     Document Type: Article

References (46)

1. Ahn, M., Witting, S.R., Ruiz, R., et al. (2011). Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules. Hum. Gene Ther. 22, 1483-1497.
2. An, D.S., Qin, F.X., Auyeung, V.C., et al. (2006). Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 14, 494-504.
3. Bish, L.T., Sleeper, M.M., Reynolds, C., et al. (2011). Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. Hum. Gene Ther. 22, 969-977.
4. Boudreau, R.L., Martins, I., and Davidson, B.L. (2009). Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169-175.
5. Bridge, A.J., Pebernard, S., Ducraux, A., et al. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263-264.
6. Carmona, S., Jorgensen, M.R., Kolli, S., et al. (2009). Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol. Pharm. 6, 706-717.
7. Chang, C.M., Lo, C.H., Shih, Y.M., et al. (2010). Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum. Gene Ther. 21, 611-621.
8. Chen, C.J., Yang, H.I., Su, J., et al. (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73.
9. Chen, C.C., Ko, T.M., Ma, H.I., et al. (2007). Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther. 14, 11-19.
10. Chen, C.C., Sun, C.P., Ma, H.I., et al. (2009). Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol. Ther. 17, 352-359.
11. Chen, C.C., Chang, C.M., Sun, C.P., et al. (2012). Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther. 19, 25-33.
12. Chou, Y.C., Jeng, K.S., Chen, M.L., et al. (2005). Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J. Virol. 79, 1813-1823.
13. Couto, L.B., and High, K.A. (2010). Viral vector-mediated RNA interference. Curr. Opin. Pharmacol. 10, 534-542.
14. Ehlert, E.M., Eggers, R., Niclou, S.P., et al. (2010). Cellular toxicity following application of adeno-associated viral vectormediated RNA interference in the nervous system. BMC Neurosci. 11, 20.
15. Ganem, D., and Prince, A.M. (2004). Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129.
16. Giering, J.C., Grimm, D., Storm, T.A., et al. (2008). Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther. 16, 1630-1636.
17. Giladi, H., Ketzinel-Gilad, M., Rivkin, L., et al. (2003). Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 8, 769-776.
18. Grimm, D., Streetz, K.L., Jopling, C.L., et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541.
19. Grimm, D., Wang, L., Lee, J.S., et al. (2010). Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 120, 3106-3119.
20. Gu, S., Jin, L., Zhang, F., et al. (2011). Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc. Natl. Acad. Sci. U. S. A. 108, 9208-9213.
21. Iloeje, U.H., Yang, H.I., Su, J., et al. (2006). Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686.
22. Ivacik, D., Ely, A., and Arbuthnot, P. (2011). Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev. Med. Virol. 21, 383-396.
23. Ji, L., and Chen, X. (2012). Regulation of small RNA stability: methylation and beyond. Cell Res. 22, 624-636.
24. Khodr, C.E., Sapru, M.K., Pedapati, J., et al. (2011). An alphasynuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 1395, 94-107.
25. Kim, S.I., Shin, D., Choi, T.H., et al. (2007). Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol. Ther. 15, 1145-1152.
26. Klein, C., Bock, C.T., Wedemeyer, H., et al. (2003). Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125, 9-18.
27. Kwon, H., and Lok, A.S. (2011). Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 275-284.
28. Makinen, P.I., Koponen, J.K., Karkkainen, A.M., et al. (2006). Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J. Gene Med. 8, 433- 441.
29. Martin, J.N., Wolken, N., Brown, T., et al. (2011). Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 18, 666-673.
30. McBride, J.L., Boudreau, R.L., Harper, S.Q., et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 105, 5868-5873.
31. McCaffrey, A.P., Nakai, H., Pandey, K., et al. (2003). Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639-644.
32. Mingozzi, F., and High, K.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12, 341-355.
33. Morrissey, D.V., Blanchard, K., Shaw, L., et al. (2005a). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41, 1349-1356.
34. Morrissey, D.V., Lockridge, J.A., Shaw, L., et al. (2005b). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007.
35. Olejniczak, M., Galka, P., and Krzyzosiak, W.J. (2010). Sequencenon- specific effects of RNA interference triggers and micro- RNA regulators. Nucleic Acids Res. 38, 1-16.
36. Pan, Q., De Ruiter, P.E., Von Eije, K.J., et al. (2011). Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. FEBS Lett. 585, 1025-1030.
37. Rossi, J.J. (2009). Innate immunity confounds the clinical efficacy of small interfering RNAs (siRNAs). Gene Ther. 16, 579-580.
38. Schwarz, D.S., Hutvagner, G., Du, T., et al. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208.
39. Shlomai, A., and Shaul, Y. (2003). Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37, 764-770.
40. Shultz, L.D., Lyons, B.L., Burzenski, L.M., et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489.
41. Sioud, M. (2010). Recent advances in small interfering RNA sensing by the immune system. N. Biotechnol. 27, 236-242.
42. Ulusoy, A., Sahin, G., Bjorklund, T., et al. (2009). Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol. Ther. 17, 1574-1584.
43. Uprichard, S.L., Boyd, B., Althage, A., et al. (2005). Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl. Acad. Sci. U. S. A. 102, 773-778.
44. Van Der Laan, L.J., Wang, Y., Tilanus, H.W., et al. (2011). AAVmediated gene therapy for liver diseases: the prime candidate for clinical application? Expert Opin. Biol. Ther. 11, 315-327.
45. Wang, Z., Ma, H.I., Li, J., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111.
46. Witting, S.R., Brown, M., Saxena, R., et al. (2008). Helperdependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. J. Biol. Chem. 283, 2120-2128.